Skip to Main Content

After Pfizer deferred hefty price hikes under pressure from President Trump, a lawmaker is asking the company and the administration to explain the details of any agreements that may have been reached as part of the sudden about-face.

Specifically, Sen. Ron Wyden (D-Ore.) wants to know if Pfizer (PFE) received any preferential treatment; what, if any, steps must be taken by the government for Pfizer to further delay price hikes; explain how the administration avoided interfering with any contracts Pfizer has with Medicare Part D plans; and whether the administration plans to approach other drug makers, among other things.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.